Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Voxalatamab | Bispecific mAb | G4;G4 | Kappa;Lambda | Phase-I | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFKSDAMHWVRQAPGKGLEWVSEISGSGGYTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSYDSSLYVGDYFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,021 | na | FOLH1;CD3E | Janssen Research & Development | na | Solid tumours | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFK SDA MHWVRQ APGKGL EWVSEI SGSGGYTNYADSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR DSYDSS LYV GDY F DYWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPL TF GQGT KVEI K |
Vudalimab | Bispecific Mixed mAb and scFv | G1;G1 | Kappa;Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS | EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK | None;None | None;None | 5tru:HL:hl/5xj3:AB:DE:GH:JK/6jc2:HL/6rp8:HL:hl/7elx:HL:hl;None | 2,020 | 2021 | CTLA4;PDCD1 | Xencor | na | Solid tumours | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVSFISY DGNNK YYAD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYC ARTGWLGPFDYWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSSPWTFGQGT KVEI K |
Vulinacimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSGISGSGGTTHYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKGLWFGEGLWGQGTLVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQSLYYRSGYTFLDWYVQKPGQSPQLLIYQSSKRDSGVPDRISGSGSGTDFTLRISRVEAEDVGVYYCFQGTHWPYTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | VEGFR2 | Henlix | na | na | Solid tumours | na | null | Q VQLVQS GGG LV QPGG SLRLSCA ASGF SFSTYAMSWVR QAPGKG LEWVSGI SGSGGT THY ADSVKG RFTISR DNSKN TVNLQM N SL RAEDT AVYYC AKG LWF GEGLWGQG TLVTVS S | DV VMT QSPLSLP VT LGQPA SISC RSSQ SLYYR SGY TFLDWYV QKPGQSP QLLIYQS SKRDSGVPD RIS GSGSGT DFTLRISRVE AEDV GVYYCF QGTHWPY T FGQGT KLEI K |
Vunakizumab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEVHWVRQAPGQGLEWMGVIDPGTGGVAYNQKFEGRVTMTADTSTSTAYMELRSLRSDDTAVYYCTRYSLFYGSSPYAMDYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCSASSSVNYMHWFQQKPDQSPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLEAEDAATYYCQQRSSYPWTFGQGTKLEIK | na | na | null | null | null | 2,016 | 2017 | IL17A | Atridia;Jiangsu Hengrui Medicine Co. | na | Plaque psoriasis;Psoriasis;Spondylarthritis | Autoimmune disorders | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TF T DYEVHWVRQ APGQG LEWMGVI DPGTGG VAY NQ KF E GRVTMTA DTSTS TAYMELRSL RSDDT AVYYCTRYSLF YGSSPYA M DYWGQG TLVTVS S | E IVLTQ SPDFQSVTPKE KVTITCS ASSSVN YMHWF QQKPDQSP KLWIYRT SNLASGVPS R FSGSGSGTD YTLTINS LE A ED AAT YYCQ QRSSYPW T FGQGT KLEI K |
Xaluritamig | Bispecific Mixed mAb and scFv | G1;na | Kappa;Lambda | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEWMGEILPGSGQTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL | None;None | None;None | None;None | 2,022 | na | STEAP1;CD3 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFSTYWIEWVR QAPGQ RLEWMGEI LPGSGQTDFNEKFQG RVTFTA DTSSDT AYMELSS LRSEDT AVYYCT RWGYYGTRG YFNVW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASSS VSYMHWFQ QKPGQAP RLLIYS TSNLASGIP ARFS GSGSGTD YTLTIS SLEPED FAVYYCQ QRRSFPY T FGQGT KLEI K |
Xeligekimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGMSMSDYWMNWVRQAPGKGLEWVAAINQDGDEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDLISDYYIHYWYFDLWGRGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQNVHNRLTWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNGSPTTFGQGTKVEIK | na | na | null | null | null | 2,021 | na | IL17A | Genrix Biopharmaceutical | na | Psoriasis | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGMS MSDYWMNWVRQ APGKG LEWVAAIN QDGD EKYYVGSVKGRFTISR DNAKN SLYLQMNSLRV EDT AVYYCVR DYYDLISDY YIHYWYFD LWGRG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQNVHN RLTWYQ QKPGKAP KLLIYG ASNLESGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYCQ Q YNGSPTTFGQGT KVEI K |
Xentuzumab | Whole mAb | G1 | Lambda | Phase-II | Active | QVELVESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGKGLELVSSITSYGSFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNMYTHFDSWGQGTLVTVSS | DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYDNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSRDTYGYYWVFGGGTKLTVL | na | na | null | null | null | 2,015 | 2016 | IGF1&IGF2 | Boehringer Ingelheim;Eli Lilly | na | Breast cancer;Prostate cancer | Non-small cell lung cancer;Solid tumours | MorphoSys HuCAL Phage Display | null | Q VELVE SGGG LV QPGG SLRLSC AASGF TFTSYWMSWVR QAPGKG LELVSSIT SYGS FTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RNM YTHF DSWGQG TLVTVS S | DI VLT QPPSVSGAPGQ RVTISC SGSSSNIGSNS VSWYQ QLPGTAP KLLIY DNSKRPSGVPDRFSGSKSGTS ASLAIT GLQSEDEA D YYCQ SRDTY GYYWVF GGGT KLTV L |
Zagotenemab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVQLVQSGAEVKKPGESLKISCKGSGYTFSNYWIEWVRQMPGKGLEWMGEILPGSDSIKYEKNFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARRGNYVDDWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRSSQSLVHSNQNTYLHWYQQKPGQAPRLLIYKVDNRFSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCSQSTLVPLTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | MAPT | Eli Lilly | na | na | Alzheimer's disease | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGY TF S N YWIEW VR QMPGKGL EWMGEI LPGSDS IKYEK NFKG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RRGN YV DDWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR SSQS LVH SNQNT YLHWYQ QKPGQAP RLLIYKV DNRFSGIPDRFSGSGSGT DFTLTISR LEPED FAVYYC SQST LVPLTF GGG TKVEI K |
Zalifrelimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLMGPFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | CTLA4 | 4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma | na | Non-small cell lung cancer;Cervical cancer;Cancer;Haemangiosarcoma;Soft tissue sarcoma;Sold tumours | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV GLMGPF DI WGQG TMVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRY LGWY QQKPGQAP RLLIYG ASTRATGIPDRFSGSGSGTD FTLTITR LEP ED FAVYYCQ QYGSSPW T FGQGT KVEI K |
Zalutumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | na | na | null | null | null | 2,005 | 2006 | EGFR | Danish Head and Neck Cancer Group;Genmab | na | na | Head and neck cancer;Colorectal cancer;Non-small cell lung cancer | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSTYGMHWVRQ APGKG LEWVAVIW DDGS YKYY GDS VKGRFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDG ITMVRGVM KDYFDYWGQG TLVTVS S | AI QLT QSPSS LSAS VGD RVTITCR ASQDIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSESGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGG TKVEI K |
Zamerovimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYIMLWVRQAPGQRLEWIGDIYPYYGSTSYNLKFKGKATLTVDTSASTAYMELSSLRSEDTAVYYCARQGGDGNYVLFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVGTTVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPFTFGQGTKLEIK | na | na | null | null | null | 2,021 | na | Rabies Virus Spike Glycoprotein G | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYSFTD YIMLWVRQ APGQ RLEWIGDI YPYYGST SYNLKF KG KATLTVD TSAST AYMELS SLRSEDT AVYYCAR QGGDGN YVLFDY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQNVG TTVAWYQ QKPGKAPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTISS LQP EDFA TYYCQ QYNSYPF TF GQGT KLEI K |
Zampilimab | Whole mAb | G4 | Kappa | Phase-I/II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTLSTHAMSWVRQAPGKGLEWVATISSGGRSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARLISTYWGQGTLVTVSS | DITMTQSPSSLSASVGDRVTITCKASQDINSYLTWFQQKPGKAPKILIYLVNRLVDGVPSRFSGSGSGQDYALTISSLQPEDFATYYCLQYDDFPYTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | TGM2 | UCB | na | Autoimmune disorders | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TLSTHAMSWVR QAPGKG LEWVATIS SGGRS TY YPDSVK GRFTISR DNSKN TLYLQMN SLRAED TA VYF CARL I STY WGQG TLVTV SS | DIT MT QSPSS LSA SVGD RVTITCK ASQD INSYLTWFQ QKPGKAP KILIYLVN R LVDGVPS R FSGSGSGQD YALTIS SLQPEDF ATYYCLQ YDDFPY T FGQGT KVEI K |
Zanidatamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/4ub0:HL/5xhf:BA:DC/ | None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC | 1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,019 | 2020 | ERBB2;ERBB2 | Zymeworks | na | Gastric cancer;Oesophageal cancer;Breast cancer;Solid tumours | Ovarian cancer | na | Biparatopic Bispecific | E VQLVES GGG LV QPGG SLRLSC AASGF TFA D YTM DWV R QAPGKGL EWVG DVNPNSGGS IY NQRFKG RFTFSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQD VSIGVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGT DFTLTISS LQPEDF ATYYCQQYYIY PATFGQGT KVEI K |
Zanolimumab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK | na | na | null | null | null | 2,004 | 2004 | CD4 | Emergent BioSolutions;Genmab | na | na | Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis | Medarex HuMAb Mouse | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCARVINWF DPWGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQD ISSWLAW Y QHKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFAT YYC QQANSFPY T FGQGT KLEI K |
Zansecimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIK | na | na | null | null | null | 2,020 | na | ANGPT2 | Eli Lilly | na | COVID-19 | Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYSFTDY NMVWVRQ APGQG LEWMGYI DPYNGGTGYNQ KFEGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR TRDRY DVWYFDV WGQG TLVTVS S | DI QMT QSPSS VSAS VGD RVTITCK ASQD VYIAVAWYQ QKPGKAP KLLIYWAS TRDTGVPS R FSGSGSGTD FTLTISS LQPEDF ATYYCHQ YSSYPPTFGGG TKVEI K |
Zelminemab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS | DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIK | na | na | null | null | null | 2,019 | 2020 | ADCYAP1R1 | Amgen | na | Migraine | na | na | null | Q VQLVE SGA EVV KPGA SVKVSCK ASGF TFSRFAMHWVRQ APGQGL EWMGVISY DGGNK YYAESV KG RVTMTR DTSTS TLYMELS SLRSEDT AVYYCA RGY DVL TGYPDYWGQG TLVTVS S | DI QLT QSPS FLSA SVGD RVTITCR ASQSIGR SLHWYQ QKPGKAP KLLIKYA SQSLSGVPS RF SGSGSGT EFTLTISS LQPEDF ATYYCH QSSRLP FTF GPGT KVDI K |
Zeluvalimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGSQTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWGQGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIK | na | na | null | null | null | 2,020 | na | PDCD1 | Amgen | na | Solid tumours | na | na | (June '22: Corrected CDRH1 sequence) | E VQLLES GGG LV QPGG SLRLSC AASGF TFSS YDM SWVR QAPGKGL EWVSLIS GGGSQ TYYAES VKG RFTISR DNSKN TLYLQMN SLRAED TAVYFCA SPSGH YFYAMD VWGQG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISNWLAWYQ QKPGKAP KLLIFAA SSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QAESFPHTFGGGT KVEI K |
Zenocutuzumab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK | QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK | 5o4o:BA/5o7p:BA;5o4g:BA | None;None | None;None | 2,017 | 2018 | ERBB3;ERBB2 | Merus | na | Breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer | Endometrial cancer;Ovarian cancer | GlymaxX Technology | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPNSGGTNY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCAR DHGSRH FWSYWGFD YWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSYSTPPTFGQGT KVEI K |
Zeripatamig | Bispecific mAb | G1;G1 | Kappa;Lambda | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQMHPRAPKTFGQKTKVEIK | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS | NFMLTQPHSVSESPGKTVTISCTRSSGSIEDKYVQWYQQRPGSSPTIVIYYDNERPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDQSLYGWVFGGGTKVTVL | None;None | None;None | None;None | 2,022 | na | CD47;CD19 | TBC | TBC | TBC | TBC | TBC | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK SYGA F DYWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ MHPRAPKTFGQK TKVEI K |
Zifibancimig | Whole mAb | G1;G1 | Kappa | TBC | Active | SEHLVESGGGLVKPGGSLRLSCATADFFEYDDMSWVRQAPGKGLEWVGSISPKGDHKYLNTKFIGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVGFFDWWGQGTLVTVSS | AIYMHQEPSSLSASVGDRVTITCHGSYWLNSEVAWYQQKPGKAPKLLIFDGDFKVYEVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGHGTKVEIK | na | na | null | null | null | 2,022 | na | ANPT2 | TBC | TBC | TBC | TBC | TBC | Biparatopic Bispecific with same V region | SEH LVES GGG LV KPGG SLRLSC ATADF FE YDDM SWVRQ APGKGL EWVGSI SPKGDHK YL NT KFIGRFTISR DDSKN TLYLQMNS LRAEDT AVYYCA RDVG FF DWWGQG TLVTVS S | A IYMH QEPSS LSAS VGD RVTITCH GS YWL NS EVAWYQ QKPGKAP KLLIF DGD FKVYEV PSRFSGSGSHED YTLTISS LQ PEDFATYYCQQ YRYHPYTFGHGT KVEI K |
Zigakibart | Whole mAb | G4 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQGLEWMGYINPYNDAPKYNEKFKGKATMTSDTSASTAYMELSSLRSDDTAVYYCARGLGYALYYAMDYWGQGTTVTVSS | DIVMTQSPSTLSASVGDRVTITCKASQNVGNNVAWYQQKPGKAPKLLISSASNRDSGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNIYPFTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | TNFSF13 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYVMHWVR QAPGQGL EWMGYI NPYNDAPKYNEKFKG KATMT SDTSAS TAYMELS SLRSDDT AVYYCA RGLG Y ALYYAM DYWGQGT TVTVS S | D IVMT QSPS TLSAS VGD RVTITCK ASQNVGNN VAWYQ QKPGKAP KLLISS ASNRDSGVPS RF SGSGSGT EFTLTIS SLQP DDFATYFCQQ YNIY PFTF GQGT KLEI K |
Ziltivekimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | IL6 | AstraZeneca;Corvidia | na | Cardiovascular disorders | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TIS SN YMIWVRQ APGKGL EWVSDLYYY AGD TYYA DSVKG RFTMSR DISKN TVYLQMN SLRAEDT AVYYCAR WADDHPPW IDL WGRG TLVTV SS | DIQ MT QSPS TLSAS VGD RVTITCR ASQGIS SW LAWY QQKPGKAP KVLIYK ASTLESGVPS R FSGSGSGT EFTLTISS LQPDDF ATYYCQQ SWLGGSFGQGT KLEI K |
Zilovertamab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGWYYFDYWGHGTLVTVSS | DIVMTQTPLSLPVTPGEPASISCRASKSISKYLAWYQQKPGQAPRLLIYSGSTLQSGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIK | na | na | null | null | null | 2,020 | na | ROR1 | University of California;Oncternal Therapeutics;Merck | na | Breast cancers;Chronia lymphocytic leukemia;Mantle cell leukemia;Lymphoma | na | na | (June '22: Corrected FWL2 sequence) | Q VQLQE SGPGLVKPSQ TLSLTCTV SGY AFTAYNIHWVRQ APGQG LEWMGSF DPYDGGSSYNQKFKD RLTISK DTSKN QVVLTMT NMDPVDT ATYYC ARG WYYFD YWGHG TLVTVS S | DI VMT QTPLSLPVTPGEPA SISCR AS KSISKYLAWYQ QKPGQAP RLLIYS GSTLQSGIPPRFSGSGYGTD FTLTI NNIES EDAAYYFCQQ HDESPY T FGEGT KVEI K |
Zimberelimab | Whole mAb | G4 | Lambda | Approved | Active | QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL | na | na | null | null | null | 2,020 | na | PDCD1 | Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology | Hodgkin's disease | Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours | na | na | null | QL QLQE SGPGL V KPSE TLTLTCTVS ADSISST TYYWVWIR QPPGKGL EWIGSISY SGS TYY NPSLK SRVTVSVD TSKN QFSLKLNS VAATD TALYYCARH LGYNGR YL PFDYWGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVG FYNYVSWY Q QHPGKAP ELMIYD VSNRPSGVSDRFSGSKSGN TASLTIS GLQAEDEAD YYC SSYT SISTWVF GGGT KLTV L |
Zinlirvimab | Whole mAb | G1 | Lambda | Phase-I | Active | QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS | SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL | na | na | 6orn:AB:FI:OP/6udk:AB:FI:OP/6udj:AR:KL:QB/6v8z:DE:PQ:JK/6ccb:DE:HL/6okp:KL | 5t3x:HL/5t3z:HL | 4fq2:HL | 2,022 | na | HIV-1 gp120 V3 | TBC | TBC | TBC | TBC | TBC | null | Q VQLQE SGPGL V KPSE TLSVTCSV SGDSMNN YYWTWIRQ SPGKGL EWIGYIS DRESA TY NPSLNS RVVISR DTSKN QLSLKL NSVTPADT AVYYCATA RRGQ RIYGVVSF GE FFYYYSMDV WGKG TTVTVS S | SYVRP LSVA LGE TARISC GRQALGSR AVQWYQ HRPGQAP ILLIY NNQDRPSGIPERFSGTPDINFGT RATLTISGV EAGDEA DYYCHMWD SRSG FSWSF GGA TRLTV L |
Zolbetuximab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS | DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK | na | na | null | null | null | 2,017 | 2018 | CLDN18 | Ganymed Pharmaceuticals | na | Gastric cancer;Oesophageal cancer;Pancreatic cancer | Solid tumours | na | Zolbetuximab and Claudiximab are the same mAb | QV QLQ QPGA ELV RPGA SVKLSCK ASGY TFTSYWINWVK QRPGQG LEWIGNI YPSDSYTNYNQKFKDK ATLTVD KSSS TAYMQL SSPTSEDS AVYYCTR SWRGNS F D Y WGQG TTLTVS S | D IVMT QSPS SLTVT AGE KVTMSC KSSQS L LNSGNQK NYLTWYQ QKPGQPP KLLIYWAS TRESGVPDR F TGSGSGTD FTLTISSV QAED LAVYYC QNDYSYP FTF GSGT KLEI K |
Zuberitamab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS | DIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK | na | na | null | null | 3bky:HL | 2,019 | 2020 | MS4A1 | Zhejiang Hisun Pharmaceutical | na | na | Diffuse large B-cell lymphoma | na | Chimeric. (June '22: Corrected CDRH2 sequence) | E VQLQQ SGA ELV RPGA SVKMSCK ASGY TFTSYNMHWVK QTPRQGL EWIGAI YPGNGDTSYNQKFKG KATLTVD KSSST AYMQLS SLTSEDS AVYFCARVVYY SNS YWYFDVW GTGT TVTVS S | DI EL SQSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIY APSNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQQWS FNPPTFGAGT KLEI K |